Abstract
The University of Central Florida invention is a method to coat active pharmaceutical ingredient (API) powders with atomically thin layers of biocompatible metal oxide films such as aluminum oxide. The metal oxide films provide a barrier that controllably dissolves and releases the APIs in different pH environments, particularly in the human gastrointestinal (GI) tract. The thickness of the film (only a few tenths of nanometers) and the precise atomic-scale engineering control the composition. Hence, the film dissolution rate provides an entirely new approach to developing API release technology that is highly controllable and less bulky (compared to current enteric formulations used as a standard by the industry). Fine-tuning the composition to respond to the specific chemistry of the GI tract can lead to highly targeted drug release or delayed drug release over time. Together, these advantages can lead to better patient outcomes and a step closer to customizable drug delivery for personalized medicine.
Partnering Opportunity
The research team is seeking partners for licensing, research collaboration, or both.
Stage of Development
Prototype available.
Benefit
Provides a barrier that controllably dissolves and releases the active pharmaceutical ingredients in different pH environments, such as the human gastrointestinal (GT) tractEnables a single system for achieving both targeted and delayed drug releaseCan lead to increased potency per unit volume of an ingested tabletMarket Application
Drug and pharmaceutical companiesPublications
“Atomic Layer Deposition (ALD) on
5-Aminosalicylic for Delayed and Targeted Drug Release Treatment of Inflammatory
Bowel Disease,” ALD 2022, 22nd International Conference on Atomic
Layer Deposition, June 28, 2022, Ghent, Belgium.
Brochure
